Who We Are

A clinical-stage computational medicine company pioneering a new paradigm in the treatment of Functional Gastrointestinal Disorders (FGIDs) 

STX-101 + ClinEffect: A Phase 2-ready 5-HT3 receptor partial agonist combined with an “always-on” clinical trial SaMD platform  

Informed by predictive processing, we integrate 1st-in-class pharmacology with a drug-led Software-as-a-Medical-Device (SaMD) combination product, combining clinically-validated mechanisms with the Clinical Trial Effect 

Major Low Anterior Resection Syndrome (LARS) - a debilitating FGID affecting 70K U.S. rectal cancer survivors with no approved drug therapy